Stan Rose

Stan Rose (born February 2, 1956) is an American biologist, biotechnology executive, and serial entrepreneur. Born in the Bronx, New York, and raised in Greenburgh, New York, Rose earned his B.A. from Cornell University in 1978 and his Ph.D. from the Massachusetts Institute of Technology in 1985.
In his professional career, Rose has spent over three decades working with leading scientists and clinicians to commercialize inventions related to genome analysis. He has raised more than $100 million in funding for early stage companies that have gone on to create more than $1 billion in shareholder value. Since 2008, he has served as President of Rose Ventures, an advisory and investment firm that works with early stage companies developing innovative, high-impact life science products and services. 
Through April 2021 Dr. Rose served as Executive Chairman of Eurofins-TGI following the 2019 acquisition of Transplant Genomics Inc. (TGI) by Eurofins Scientific SE (ERF.PA). Rose was co-founder, Director and CEO of TGI, a molecular diagnostics company commercializing tests to help physicians better assess adequacy of immunosuppression for organ transplant recipients, and thereby improve outcomes.
Rose is a Director of Invenra, a biotechnology company focused on the discovery and development of multi-specific antibodies for immuno-oncology. 
Rose is a Senior Fellow with the Council on Strategic Risks, participating in The Alliance to End Biological Threats.
Rose was a Director of Cellular Dynamics International, a leader in pluripotent stem cell technology for drug discovery and cell therapy acquired by FujiFilm in 2015, and Chair of the Market Advisory Board of Cyvek, a protein immunoassay and immunodiagnostics company acquired by Bio-Techne in 2014.
Highlights from earlier in his career include serving as CEO of NimbleGen Systems, Inc., a genomics tool company, from 2003 through its acquisition by Roche in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s. 